Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective.

Authors:
Camelo RM; Barbosa MM; Henriques LCM; Martin AP; Godman B and 3 more

Journal:
Saudi Pharm J

Publication Year: 2023

DOI:
10.1016/j.jsps.2023.101867

PMCID:
PMC10661532

PMID:
38028212

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Saudi Pharm J

Abbreviation: Saudi Pharm J

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A comprehensive quality control and cost comparison study of branded and generic angiotensin recept…
Sharma AK; Rastogi S; Ali F and 2 more (2024) - Transparency Score: 3/6
A content-quality and optimization analysis of YouTube as a source of patient information for bipol…
Alsabhan JF; Almalag HM; Abanmy NO and 3 more (2024) - Transparency Score: 4/6
A detailed review of pharmacology of MFN1 (mitofusion-1)-mediated mitochondrial dynamics: Implicati…
Alghamdi A. (2024) - Transparency Score: 2/6
Are drug safety measures harmonized? A real-world evidence from three regulatory authorities.
Alelayan S; Al-Sheikh L; Almotawa R and 2 more (2024) - Transparency Score: 3/6
Chemical profile and biological properties of the <i>Piper corcovadense</i> C.DC. essential oil.
Henrique Fontoura B; Cristina Perin E; Paula Buratto A and 9 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"appendix a supplementary material the following are the supplementary data to this article: supplementary data 1 supplementary data 2 acknowledgments we acknowledge dr."

Code Sharing
Evidence found in paper:

"6 Declaration of competing interests RMC received speaker fees from Bayer, NovoNordisk, Hoffman-La Roche, and Takeda; consultancy fees from Hoffman-La Roche and Takeda, and scientific event grants from Bayer, NovoNordisk, Hoffman-La Roche, and Takeda. MMB, LCMH, APM, BG, AAGJ, FAA, and JAT declare no competing conflict of interest. Declaration of competing interest RMC received speaker fees from Bayer, NovoNordisk, Hoffman-La Roche, and Takeda; consultancy fees from Hoffman-La Roche and Takeda, and scientific event grants from Bayer, NovoNordisk, Hoffman-La Roche, and Takeda. MMB, LCMH, APM, BG, AAGJ, FAA, and JAT declare no competing conflict of interest."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025